Feedback
Settings

Settings

Goto Application

83,003 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(NYHBQMYGNKIUIF-UUOKFMHZSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 8,301
1.WO/2025/242026CANCER VACCINES AND USES THEREOF
WO - 27.11.2025
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
 Appl.No PCT/CN2025/095665 Applicant EVEREST MEDICINES (CHINA) CO., LTD. Inventor XIE, Liang
Provided herein are nucleic acids, pharmaceutical compositions and vaccines that express two or more cancer antigens. Also provided herein are methods for treating a cancer.
2.WO/2025/245056GASTRIC CANCER RNA BIOMARKERS AND USES THEREOF
WO - 27.11.2025
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
 Appl.No PCT/US2025/030114 Applicant CITY OF HOPE Inventor GOEL, Ajay
Methods of diagnosing, monitoring, or treating gastric cancer (e.g., early gastric cancer) in a patient are accomplished by detecting the expression levels of RNA biomarkers (e.g., microRNA biomarkers) in a biological sample. Such RNA biomarkers include, for example, miR-21-3p, miR-21-5p, miR-215-5p, miR-335-3p, miR-27a-3p, miR-95-3p, miR-181b-5p, miR- 431-5p, miR-1246. miR-192-3p. miR-196a-5p, miR-183-5p, and miR-135b-5p. The RNA biomarkers can be cell-free miRNA, exosomal miRNA, or a combination thereof, such as cell-free miR-21-3p, cell-free miR-21-5p, cell-free miR-215-5p, cell-free miR-335-3p, cell-free miR- 27a-3p, cell-free miR-95-3p, cell-free miR-181b-5p, cell-free miR-431-5p, exosomal miR-21- 3p, exosomal miR-21-5p, exosomal miR-1246, exosomal miR-192-3p, exosomal miR-215-5p, exosomal miR-27a-3p, exosomal miR-95-3p, exosomal miR-196a-5p, exosomal miR-183-5p, and exosomal miR-135b-5p.
3.WO/2025/240992AGENTS FOR TREATMENT OF CONDITIONS ASSOCIATED WITH OPTIC ATROPHY 1
WO - 27.11.2025
Int.Class C07K 14/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
 Appl.No PCT/AU2025/050177 Applicant PYC THERAPEUTICS LIMITED Inventor MARTIN, Adam
The present disclosure generally relates to a cell-penetrating peptide (CPP) comprising a sequence set forth in SEQ ID NO: 2504 and conjugates thereof. The present invention also relates to antisense oligonucleotides that modulates mRNA productive transcript, stability and/or translation of OPA1 gene transcript or part thereof linked to a cell-penetrating peptide (CPP) comprising a sequence set forth in SEQ ID NO: 2504.
4.WO/2025/245492COMPOSITIONS AND METHODS FOR T CELL MANUFACTURING AND USES THEREOF
WO - 27.11.2025
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
 Appl.No PCT/US2025/030846 Applicant BIONTECH US INC. Inventor VAN BUUREN, Marit M.
Provided herein are methods of producing a plurality of T cells which has been ex vivo stimulated and expanded to enrich for antigen-specific T cells. This plurality of T cells can be used to provide highly specific and efficacious T cell therapies for treatment of cancers and other conditions.
5.WO/2025/245111IMMUNORECEPTOR TARGETING PROTEINS AND RELATED METHODS
WO - 27.11.2025
Int.Class C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
 Appl.No PCT/US2025/030194 Applicant FLAGSHIP PIONEERING INNOVATIONS VII, LLC Inventor BANDUKWALA, Hozefa Saifuddin
Provided herein are immunoreceptor targeting proteins and compositions (e.g., pharmaceutical compositions) comprising the same; as well as methods of making the immunoreceptor targeting proteins and compositions. The immunoreceptor targeting proteins provided herein are useful in pharmaceutical compositions and methods of use (including, e.g., binding to (e.g., thereby targeting) cells expressing CD30L, inhibiting binding or reducing (e.g., preventing) of one or more TNSRSF member to one or more TNFLSF member (e.g., binding of CD30L to CD30).
6.WO/2025/242321NOVEL USE
WO - 27.11.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/EP2024/080642 Applicant GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED Inventor ELSTON, Robert Conrad
The present invention relates to a treatment regimen for chronic hepatitis B capable of eliciting high levels of functional cure comprising sequential treatment with one or more RNAi agents and an antisense oligonucleotide.
7.WO/2025/242771NOVEL USE
WO - 27.11.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/EP2025/064057 Applicant GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED Inventor ELSTON, Robert Conrad
The present invention relates to a treatment regimen for chronic hepatitis B capable of eliciting high levels of functional cure comprising sequential treatment with one or more RNAi agents and an antisense oligonucleotide.
8.WO/2025/245486COMPOSITIONS AND METHODS FOR T CELL MANUFACTURING AND USES THEREOF
WO - 27.11.2025
Int.Class C12N 5/0783
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0783T cells; NK cells; Progenitors of T or NK cells
 Appl.No PCT/US2025/030840 Applicant BIONTECH US INC. Inventor ARIETA, Christina, M.
Provided herein are methods of producing a plurality of T cells which has been ex vivo stimulated and expanded to enrich for antigen-specific T cells. This plurality of T cells can be used to provide highly specific and efficacious T cell therapies for treatment of cancers and other conditions.
9.WO/2025/242248METHOD OF PRODUCTION OF CLADRIBINE
WO - 27.11.2025
Int.Class C12P 19/40
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
26Preparation of nitrogen-containing carbohydrates
28N-glycosides
38Nucleosides
40having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides
 Appl.No PCT/CZ2025/050048 Applicant VUAB PHARMA A.S. Inventor MAŤHA, Vladimír
The invention relates to a method of producing cladribine with a purity greater than 99.9 wt.% from 2-deoxyuridine and 2-chloroadenine by using the catalytic action of high concentrations (at least 20.000 U/L) of freely dissolved transglycosidases UP (uridine phosphorylase) and PNP (purine nucleoside phosphorylase) in an enzymatic synthesis in an aqueous environment without the presence of any organic solvent.
10.WO/2025/245188METHODS OF TREATING LIVER STEATOSIS AND NON-ALCOHOLIC FATTY LIVER DISEASE
WO - 27.11.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/US2025/030316 Applicant FLAGSHIP PIONEERING INNOVATIONS VII, LLC Inventor VON HERRMANN, Katharine Maryell
Disclosed herein are methods for treating subjects having or at risk of developing liver steatosis or non-alcoholic fatty liver disease.
# -